- Home
- BFST vs BBNX Comparison
BFST vs BBNX Comparison
Compare BFST & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | BBNX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 997.9M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BFST | BBNX |
|---|---|---|
| Price | $32.35 | $16.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $37.05 | $25.10 |
| AVG Volume (30 Days) | 143.3K | ★ 1.1M |
| Earning Date | 10-26-2026 | 10-27-2026 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | 23.45 | ★ 78.95 |
| EPS | ★ 2.08 | N/A |
| Revenue | $10,704,000.00 | ★ $100,251,000.00 |
| Revenue This Year | $14.30 | $25.22 |
| Revenue Next Year | $6.61 | $47.09 |
| P/E Ratio | $15.67 | ★ N/A |
| Revenue Growth | 1.20 | ★ 53.94 |
| 52 Week Low | $24.19 | $8.80 |
| 52 Week High | $33.69 | $32.71 |
Technical Indicators
Market Signals| Indicator | BFST | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 47.09 |
| Support Level | $30.86 | $15.92 |
| Resistance Level | $33.69 | $18.20 |
| Average True Range (ATR) | 0.83 | 1.65 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 57.69 | 31.59 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.